This project is supported by the Global Health EDCTP3 Joint Undertaking and its members
This project has received funding from the European Union’s Horizon Europe research and innovation programme under grant agreement No 10110308
Federal Department of Economic Affairs, Education and Research EAER
State Secretariat for Education,
Research and Innovation SERI
Copyright 2024 STOP2030 | All Rights Reserved | Powered by Mundo Sano
The Ghana Health Service is a Public Service body established under Act 525 of 1996 as required by the 1992 constitution. It is an autonomous Executive Agency responsible for implementation of national policies under the control of the Minister for Health through its governing Council – the Ghana Health Service Council.
GHS aims to provide and prudently manage comprehensive and accessible health service with special emphasis on primary health care at regional, district and sub-district levels in accordance with approved national policies. Its mission is to provide all communities with timely, quality and comprehensive health care.
The Kenya Medical Research Institute is a State Corporation established in Kenya in 1979 through the Science and Technology (Repealed) Act, Cap 250 of the Laws of Kenya operated under the Science Technology and Innovation Act, 2013 as the national body responsible for carrying out research in human health in Kenya.
KEMRI has grown from its humble beginning over 40 years ago to become a regional leader in human health research.
The Institute currently ranks as one of the leading Centres of excellence in health research both in Africa as well as globally.
Liconsa is a research facility within Chemo. Chemo is part of the Spanish multinational Insud Pharma, which has been operating for over 45 years and has a team of 7,000 professionals worldwide. Insud Pharma is present at every level of the chemical and pharmaceutical industry through its three highly synergistic business units: industrial (Chemo), brand (Exeltis) and biotechnology (mAbxience). Our overarching goal is to protect and improve people’s health and wellbeing.
Chemo is a sector leader in the research, development and manufacturing of a broad variety of active pharmaceutical ingredients (APIs) and a full range of Finished Dosage Forms (FDFs) for both human and veterinary use in the main treatment areas.
Liconsa is a research facility within Chemo. Chemo is part of the Spanish multinational Insud Pharma, which has been operating for over 45 years and has a team of 7,000 professionals worldwide. Insud Pharma is present at every level of the chemical and pharmaceutical industry through its three highly synergistic business units: industrial (Chemo), brand (Exeltis) and biotechnology (mAbxience). Our overarching goal is to protect and improve people’s health and wellbeing.
Chemo is a sector leader in the research, development and manufacturing of a broad variety of active pharmaceutical ingredients (APIs) and a full range of Finished Dosage Forms (FDFs) for both human and veterinary use in the main treatment areas.
Mundo Sano is a scientific, nongovernmental foundation based in Argentina and Spain. It was founded in 1993 by Dr Roberto Gold and was regarded as a family legacy with a clear mission: giving back to society part of what has been received. Since then, Mundo Sano has sought cooperation from the private sector with the State with the commitment to contribute to Public Health.
Both in their own offices in Latin America and Spain, and in other locations (through partners that provide local leadership) Mundo Sano implements programs that seek to efficiently overcome the barriers that hinder people’s access to health, thereby generating useful evidence for public policies.
The Foundation receives broad cooperation, but it is fundamentally supported by the Insud / Insud Pharma Group.
Mundo Sano is a scientific, nongovernmental foundation based in Argentina and Spain. It was founded in 1993 by Dr Roberto Gold and was regarded as a family legacy with a clear mission: giving back to society part of what has been received. Since then, Mundo Sano has sought cooperation from the private sector with the State with the commitment to contribute to Public Health.
Both in their own offices in Latin America and Spain, and in other locations (through partners that provide local leadership) Mundo Sano implements programs that seek to efficiently overcome the barriers that hinder people’s access to health, thereby generating useful evidence for public policies.
The Foundation receives broad cooperation, but it is fundamentally supported by the Insud / Insud Pharma Group.
The Barcelona Institute for Global Health, ISGlobal, is the fruit of an innovative alliance between the “la Caixa” Foundation, academic institutions and government bodies to contribute to the efforts undertaken by the international community to address the challenges in global health.
ISGlobal is a consolidated hub of excellence in research that has grown out of work first started in the world of health care by the Hospital Clínic and the Parc de Salut MAR and in the academic sphere by the University of Barcelona and Pompeu Fabra University. Its working model is based on the generation of scientific knowledge through Research Programmes and Groups, and its translation through the areas of Education and Training and Analysis and Global Development.
Its ultimate goal is to help close the gaps in health disparities between and within different regions of the world.
Bridges to Development is a nonprofit organisation striving to bridge gaps in equitable access and opportunity in low and middle-income countries. Its goal is to advance economic and social well-being, especially of women and girls, by supporting opportunities for communities to overcome health and education barriers.
Virtually every country has improved its education, health, and economic situation over the past 20 years; however this opportunity has not necessarily been equitable and there is work to bridge the gap and build on the progress made. Sustainable development engages communities and stakeholders to identify solutions that are both creative and effective.
Part of Bridge’s expertise is in scaling up transforming initiatives to achieve those goals in diverse organizations such as Gavi, The Vaccine Alliance, The Global Fund and the Bill & Melinda Gates Foundation.
The Wellcome Sanger Institute is a world leader in genome research that delivers insights into human, evolutionary and pathogen biology. The Institute’s mission is to apply and explore genomic technologies at scale to advance understanding of biology and improve health. To achieve this vision GRL’s Mission is to:
